There’s limited access to California’s cheap insulin, Eli Lilly’s cracking down on black market retatrutide, and new biotech Khartis Therapeutics emerges with $95 million.

Some rather buff fellows at my gym were comparing abdomens today, raving about the bodysculpting wonders of all that illicit “reta.” I imagine they won’t be too pleased about the Lilly news.